Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Citrulline correlations in short bowel syndrome-intestinal failure by patient stratification: Analysis of 24 weeks of teduglutide treatment from a randomized controlled study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Parenteral nutrition impairs plasma bile acid and gut hormone responses to mixed meal testing in lean healthy men

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Utility of bio-electrical impedance vector analysis for monitoring treatment of severe acute malnutrition in children

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Flavonoid intake and its association with atrial fibrillation

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND & AIMS: Disease-associated factors influence parenteral support (PS) reduction in response to teduglutide in patients with intestinal failure associated-short bowel syndrome (SBS-IF). We sought to determine correlative relationships between plasma citrulline levels, small bowel length, and PS volume.

METHODS: A post hoc analysis of plasma citrulline levels from patients in the STEPS 24-week study of teduglutide in patients with SBS-IF. Plasma citrulline was assessed in all patients; patients were stratified 3 times into subgroups based on bowel anatomy, cause of SBS-IF, and baseline PS volumes. Correlation analyses used simple linear regression models. Statistical comparisons between study groups were conducted using 2-sided t tests for 2 independent mean differences.

RESULTS: Baseline plasma citrulline correlated with remnant small bowel length (r = 0.355, P = 0.002), but not with baseline PS volume (r = -0.167, P = 0.14), in the overall population. There was a robust correlation between the baseline and Week 24 citrulline (r = 0.705, P < 0.0001), and an inverse correlation between change from baseline in citrulline and PS volume from baseline to Week 24 (r = -0.359, P = 0.001). In all subgroups, patients treated with teduglutide showed numerically greater increases in plasma citrulline at Week 24 compared with placebo.

CONCLUSION: Baseline plasma citrulline showed significant correlations with small bowel length in patients with ≥50% colon remaining/no stoma/colon-in-continuity, and patients with SBS-IF causes other than IBD/vascular disease. Citrulline levels may correlate with PS changes in response to teduglutide and more research may reveal a relationship between citrulline levels within the heterogeneous population of patients with SBS-IF. NCT00798967, 2008-006193-15.

Original languageEnglish
JournalClinical Nutrition
Issue number8
Pages (from-to)2479-2486
Publication statusPublished - Aug 2020

    Research areas

  • Citrulline, Intestinal failure, Parenteral support, Short bowel syndrome, Teduglutide

ID: 59434276